
News|Articles|November 1, 2012
Truvada (Emtricitabine/tenofovir disoproxil fumarate tablets)
New combination: FDA approved the combination tablet of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (Truvada, Gilead Sciences) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 in adults at high-risk in combination with safer sex practices.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
AI Helps Managed Care Identify High-Risk Patients Sooner and More Precisely | AMCP Nexus 2025
2
Real-World Study Shows $330,000 Cost Difference Between CAR T and BiTE Therapies | AMCP Nexus 2025
3
Drug Pricing Not Main Driver of State Medicaid Spending | AMCP Nexus 2025
4
Real-World Data Drives CAR T Treatment Decisions, Reveals Benefits of Earlier Administration | AMCP Nexus 2025
5



















































